| Not Yet Recruiting | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodep NCT07137481 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | M-2018-334 in Hematological Malignancies NCT06225050 | Miltenyi Biomedicine GmbH | N/A |
| Not Yet Recruiting | Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Inject NCT07362732 | Sichuan University | EARLY_Phase 1 |
| Not Yet Recruiting | Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies NCT07362602 | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | EARLY_Phase 1 |
| Recruiting | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies NCT07220616 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Not Yet Recruiting | Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study NCT07047352 | Shanghai Jiao Tong University School of Medicine | N/A |
| Not Yet Recruiting | Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors NCT06992934 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | 18F-Pentixafor PET in Hematologic Malignancies NCT07122674 | First Affiliated Hospital of Zhejiang University | — |
| Recruiting | Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation NCT06799195 | University of Nebraska | Phase 2 |
| Recruiting | Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hem NCT06851702 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Active Not Recruiting | Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies NCT06584955 | M.D. Anderson Cancer Center | N/A |
| Withdrawn | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells NCT07071909 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Using a Population Pharmacokinetic Model to Estimate the Dosage of Teicoplanin in Patients With Hematologic Ma NCT06674330 | National Taiwan University Hospital | — |
| Recruiting | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies NCT06652633 | Galapagos NV | Phase 3 |
| Recruiting | A Clinical Study of HMPL-506 in Patients With Hematological Malignancies NCT06387082 | Hutchmed | Phase 1 |
| Recruiting | Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies NCT06150469 | University Hospital, Limoges | N/A |
| Not Yet Recruiting | Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion NCT06180499 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Not Yet Recruiting | Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade NCT06238245 | Beijing 302 Hospital | Phase 2 |
| Unknown | Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Mali NCT06258629 | Sohag University | — |
| Active Not Recruiting | Study of AZD9829 in CD123+ Hematological Malignancies NCT06179511 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting NCT07456982 | Marmara University | N/A |
| Recruiting | A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies NCT06224855 | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 |
| Unknown | Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies NCT06041815 | The First Affiliated Hospital of Soochow University | — |
| Recruiting | Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT Wi NCT05768035 | Smart Immune SAS | Phase 1 / Phase 2 |
| Recruiting | The Study of ICP-248 in Patients With Mature B-cell Malignancies NCT05728658 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 |
| Recruiting | APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU NCT05475600 | Centre Hospitalier Régional Metz-Thionville | N/A |
| Completed | CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies NCT05454241 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology NCT05306509 | Children's Hospital of Fudan University | N/A |
| Terminated | A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignan NCT05338346 | Antengene Discovery Limited | Phase 1 |
| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies NCT05347225 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell D NCT04959903 | Smart Immune SAS | Phase 1 / Phase 2 |
| Completed | Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT NCT05290545 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Recruiting | Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies NCT06550102 | University Children's Hospital, Zurich | — |
| Recruiting | A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Compari NCT06834412 | Xijing Hospital | N/A |
| Completed | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-0 NCT05005442 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects NCT04283097 | Kangpu Biopharmaceuticals, Ltd. | Phase 1 |
| Unknown | A Study of TQB3820 in Patients With Hematological Malignancies NCT05020639 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases (NICHE) - CART NCT06607289 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Unknown | Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies NCT04878822 | Ospedale di Circolo - Fondazione Macchi | — |
| Unknown | Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancie NCT04790747 | Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04634552 | Janssen Research & Development, LLC | Phase 2 |
| Not Yet Recruiting | LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies NCT04657965 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune NCT04743388 | National and Kapodistrian University of Athens | — |
| Not Yet Recruiting | Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of NCT04662788 | Zhejiang University | EARLY_Phase 1 |
| Active Not Recruiting | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma NCT04557098 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies NCT04260698 | Gamida Cell ltd | Phase 3 |
| Unknown | COVID19-hematological Malignancies: the Italian Hematology Alliance NCT04352556 | Ospedale di Circolo - Fondazione Macchi | — |
| Active Not Recruiting | Tissue Microarray of Hematological Malignancies NCT04142372 | Tampere University Hospital | — |
| Completed | Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Tri NCT04184869 | Acrotech Biopharma Inc. | Phase 1 |
| Terminated | T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. NCT02849886 | Centre Hospitalier Universitaire de Besancon | Phase 1 / Phase 2 |
| Recruiting | Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study NCT03802773 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Durvalumab and Tremelimumab for Pediatric Malignancies NCT03837899 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT NCT03733340 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Completed | Compassionate Use Study of Tenalisib (RP6530) NCT03711604 | Rhizen Pharmaceuticals SA | Phase 1 / Phase 2 |
| Unknown | Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells NCT03236129 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Active Not Recruiting | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma NCT03399799 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malign NCT03248479 | Gilead Sciences | Phase 1 |
| Unknown | Safety and Efficacy Evaluation of IM19 Cells NCT03344705 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Active Not Recruiting | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed NCT03145181 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Unknown | Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplanta NCT02828878 | Cellect Biotechnology | Phase 1 / Phase 2 |
| Terminated | Study of IV CBL0137 in Previously Treated Hematological Subjects NCT02931110 | Incuron | Phase 1 |
| Completed | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and M NCT02730299 | Gamida Cell ltd | Phase 3 |
| Completed | CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. NCT03067155 | University Hospital, Ghent | Phase 2 |
| Completed | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes NCT02680795 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic M NCT02576496 | Mundipharma Research Limited | Phase 1 |
| Completed | Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib NCT02824159 | University Hospital, Toulouse | — |
| Completed | Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant NCT02611063 | Stefanie Sarantopoulos, MD, PhD. | Phase 1 |
| Completed | MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT NCT02528682 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Completed | Impact of Child Positioning on Pain During a Lumbar Puncture NCT02834156 | Centre Hospitalier Universitaire de Nice | N/A |
| Unknown | Molecular Disease Profile of Hematological Malignancies NCT02459743 | University of Pavia | — |
| Completed | Pasireotide in Prevention of GI Toxicity NCT02215070 | Anthony Sung, MD | Phase 2 |
| Recruiting | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Ou NCT02269592 | Dana-Farber Cancer Institute | — |
| Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry NCT02298816 | Wake Forest University Health Sciences | — |
| Terminated | Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transpla NCT02199041 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | The Good Patient Study NCT02199548 | St. Jude Children's Research Hospital | — |
| Terminated | PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) NCT02074436 | Emory University | Phase 2 |
| Completed | Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) NCT02859623 | Centre Hospitalier Universitaire de Besancon | — |
| Completed | Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis NCT01916057 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycopheno NCT02300571 | Fondazione del Piemonte per l'Oncologia | — |
| Completed | A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Un NCT01830010 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis NCT02213822 | Rhode Island Hospital | — |
| Completed | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM NCT01816230 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Impact of Donor-recipient ABO Matching on Haploidentical Stem Cell Transplantation NCT05103995 | First Affiliated Hospital of Zhejiang University | — |
| Completed | A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With A NCT01725555 | Axelar AB | Phase 1 |
| Completed | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematologic NCT01607892 | Karyopharm Therapeutics Inc | Phase 1 |
| Withdrawn | Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB) NCT01235468 | Dr. Avichai Shimoni MD | Phase 1 |
| Completed | Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant NCT01627275 | Mitchell Horwitz, MD | Phase 1 |
| Withdrawn | Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignan NCT01168882 | Agennix | Phase 1 |
| Active Not Recruiting | Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens NCT01428973 | University of Liege | Phase 2 |
| Completed | A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors NCT01349101 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT NCT01246206 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the NCT01139164 | Medical University of South Carolina | Phase 2 |
| Completed | The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" NCT01172132 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers NCT00788684 | AbbVie | Phase 1 |
| Unknown | Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acu NCT00524784 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Unknown | Exercise During Chemotherapy for Patients With Hematological Malignancies NCT00884364 | Charite University, Berlin, Germany | Phase 3 |
| Completed | Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? NCT00892502 | Copenhagen University Hospital at Herlev | N/A |
| Completed | Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies NCT00886522 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Phase 2 |
| Unknown | Extracorporal Photopheresis Pilot Study NCT00930566 | Hospices Civils de Lyon | Phase 1 / Phase 2 |
| Unknown | Intrabone Cord Blood Transplantation NCT00838019 | Hospital Clinic of Barcelona | Phase 4 |
| Completed | Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantat NCT00841724 | Nantes University Hospital | Phase 2 |
| Completed | Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients NCT00824993 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Trial Of Double Umbilical Cord Blood Transplantation NCT00763490 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Pa NCT01060462 | Janssen Korea, Ltd., Korea | — |
| Completed | A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological NCT01315132 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditioning NCT00603954 | University of Liege | Phase 2 |
| Unknown | Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies NCT00580450 | University Of Perugia | Phase 1 / Phase 2 |
| Completed | A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoieti NCT01069887 | Catholic University of the Sacred Heart | — |
| Completed | Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease NCT00504803 | University of Liege | Phase 2 |
| Completed | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies NCT00506402 | CASI Pharmaceuticals, Inc. | Phase 1 |
| Completed | Rituximab for Prevention of Chronic GVHD NCT00379587 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) NCT00506948 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Reduced Intensity Haploidentical Transplant for Hematological Malignancies NCT01162096 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplan NCT00348959 | St. James's Hospital, Ireland | N/A |
| Terminated | Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients NCT01820962 | Maastricht University Medical Center | Phase 3 |
| Completed | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies NCT00438178 | Gemin X | Phase 1 |
| Unknown | MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplanta NCT00129155 | Hospices Civils de Lyon | Phase 2 |
| Completed | Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) NCT00557817 | University of Liege | Phase 2 / Phase 3 |
| Completed | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Pati NCT00088101 | Synta Pharmaceuticals Corp. | Phase 1 |
| Unknown | RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT NCT00163644 | Bayside Health | N/A |
| Completed | Intermittent Use of Aerosolized Ribavirin for Treatment of RSV NCT00500578 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | Study of ABT-751 in Patients With Refractory Hematologic Malignancies NCT00047489 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignan NCT00423124 | AGC Biologics S.p.A. | Phase 1 / Phase 2 |
| Completed | Dose-range Finding Treosulfan-based Conditioning NCT01063647 | medac GmbH | Phase 1 / Phase 2 |
| Completed | Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) NCT00179764 | Ann & Robert H Lurie Children's Hospital of Chicago | N/A |
| Completed | Nonmyeloablative Stem Cell Transplant in Elderly NCT00382759 | Azienda Ospedaliera San Giovanni Battista | Phase 2 / Phase 3 |
| Recruiting | Cologne Cohort of Neutropenic Patients (CoCoNut) NCT01821456 | University Hospital of Cologne | — |
| Completed | Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting NCT00876148 | Azienda Ospedaliera San Giovanni Battista | — |